Overview
FDA's 2026 Human Factors guidance has
changed the way medical device manufacturers determine what human factors
information belongs in a marketing submission. The May 2026 final guidance
establishes a risk-based framework that places submissions into Human Factors
Submission Categories 1, 2 or 3, while revised eSTAR templates now incorporate
this decision process directly into the submission workflow.
The challenge is that choosing the correct
category is rarely as simple as asking whether a device has critical tasks.
Manufacturers must consider whether the submission involves a new or modified
device, what has changed in the user interface, whether intended users or use
environments have changed, whether existing critical tasks are affected, what
the Use-Related Risk Analysis shows, and whether existing evidence is
sufficient to support the submission. Even a device with critical tasks may not
automatically require human factors validation data to be submitted, while
seemingly limited device changes can create a very different result when they
affect how users perceive, understand or interact with the device.
This webinar will walk participants through
FDA's Category 1, 2 and 3 decision framework and show how those decisions
connect to the URRA, critical-task analysis, human factors validation,
supporting rationale and the Human Factors section of eSTAR. Particular
attention will be given to Decision Point D, where factors such as history of
safe use, user-interface complexity and the adequacy of existing risk controls
can become central to determining whether validation data should accompany the
submission.
Using practical device-change scenarios,
participants will examine how the framework applies when software or controls
change, labeling or training is revised, new user populations are introduced,
the use environment changes, or several seemingly minor modifications
collectively affect an existing critical task. The session will also clarify
the boundary between FDA's submission-content recommendations and the broader
human factors, design-development and risk-management activities manufacturers
maintain under their quality system.
Areas Covered:
- FDA's 2026 Human Factors Submission
Framework: What Changed
- Understanding Human Factors Submission
Categories 1, 2 and 3
- Applying FDA's Decision Points to New and
Modified Medical Devices
- Use-Related Risk Analysis (URRA) and
Critical Tasks
- Determining When Human Factors Validation
Data Should Be Submitted
- Building the Rationale When Validation Data
Are Not Submitted
- Human Factors Validation Testing: Key FDA
Expectations
- What FDA Expects in Category 1, 2 and 3
Submissions
- Completing the Human Factors Section in
eSTAR
- Applying the Framework to Real-World Device
Modification Scenarios
- Human Factors, QMSR and ISO 13485:
Understanding the Boundaries
To support implementation of the concepts
discussed during the webinar, attendees will receive the following handouts:
- FDA Human Factors Category 1–2–3 Decision
& Submission Guide
- Medical Device Change → Human Factors
Impact & Validation Decision Guide
Why Should You Attend?
The difficult part of FDA's 2026 Human
Factors framework is not learning that Categories 1, 2 and 3 exist. The
difficult part is determining which category applies to your device and what
evidence supports that decision. A change to software, labeling, training,
users or the use environment can affect the analysis differently, and the
presence of a critical task alone does not provide the complete answer.
This program will help you work through
those decisions the way FDA expects them to be evaluated. You will see how the
URRA, critical tasks, existing human factors evidence, user-interface
complexity, history of use and risk controls influence whether validation data
should be submitted—and what a defensible Category 2 rationale or Category 3
submission should contain.
You will also see how these decisions
translate into the revised eSTAR workflow and how they apply to realistic
device-modification scenarios. The goal is to leave with a clearer process for
determining what changed, what needs to be evaluated, what FDA needs to see,
and how to support the conclusion before the submission reaches FDA review.
Who Will Benefit?
This webinar is designed for professionals
responsible for preparing, reviewing, supporting, or approving human factors
information for FDA medical device submissions and for teams involved in device
design, usability, risk management, and regulatory strategy.
It is especially relevant to those who must
determine the correct Human Factors Submission Category, evaluate critical
tasks, support validation decisions, or complete the Human Factors portion of
eSTAR; those include:
- Regulatory Affairs Directors
- Regulatory Affairs Managers
- Regulatory Affairs Specialists
- Medical Device Regulatory Submission Leads
- 510(k), De Novo, and PMA Submission
Professionals
- Human Factors Engineers
- Human Factors and Usability Engineering
Managers
- Usability Engineers
- User Experience Professionals Supporting
Medical Devices
- Design Assurance Engineers
- Design Quality Engineers
- Quality Assurance Directors and Managers
- Quality Systems Managers
- Risk Management Professionals
- Medical Device Risk Management Engineers
- Product Development Directors and Managers
- R&D Directors and Managers
- Medical Device Design Engineers
- Systems Engineers
- Software and Digital Health Product
Development Leads
- Clinical Engineering Professionals Involved
in Device Usability
- Medical Device Safety and Risk
Professionals
- Regulatory and Quality Consultants
Supporting Medical Device Manufacturers
Robert
H. Caldwell is a medical device quality systems and regulatory compliance
professional with extensive experience helping manufacturers strengthen risk
management, design and quality system controls, CAPA, complaint handling,
supplier quality, and FDA inspection readiness.
Throughout his career, he has worked
closely with regulatory, quality, engineering, operations, and executive teams
to evaluate product and process risks, investigate nonconformances, improve
documentation and decision-making, respond to FDA inspection findings, and
build quality systems that are practical, risk-based, and defensible. His
experience includes supporting medical device organizations through FDA
inspections, Form 483 responses, remediation activities, internal audits,
management reviews, and quality system gap assessments.
His areas of focus include FDA’s Quality
Management System Regulation (QMSR), ISO 13485, ISO 14971 risk management,
corrective and preventive action, complaint and nonconformance trending, and
the connection between product risk, design decisions, regulatory
documentation, and broader quality system evidence. This perspective is
particularly relevant when evaluating how device changes, user-related risks,
critical tasks, and supporting documentation fit within a manufacturer’s
overall regulatory and quality framework.
Known for his clear and practical teaching
style, Robert translates complex FDA and quality system expectations into
real-world decision-making. He helps teams understand how regulatory
conclusions should be supported by documented risk analysis, how changes can
affect the broader device risk picture, and how to build records that
demonstrate sound reasoning, appropriate risk controls, and defensible
compliance decisions.
Enrollment Options
Tags: FDA Human Factors, Medical Device Compliance, Human Factors Engineering, Usability Engineering, FDA 2026, Medical Device Submissions, Regulatory Affairs, eSTAR, URRA, Critical Tasks, Human Factors Validation, Category 1 2 3, 510(k), De Novo, PMA, Medical Device Risk Management, Robert, Caldwell, September 2026, Webinar

